NO20032007D0 - Radiofarmasöytiske midler for diagnose av Alzheimer's sykdom - Google Patents

Radiofarmasöytiske midler for diagnose av Alzheimer's sykdom

Info

Publication number
NO20032007D0
NO20032007D0 NO20032007A NO20032007A NO20032007D0 NO 20032007 D0 NO20032007 D0 NO 20032007D0 NO 20032007 A NO20032007 A NO 20032007A NO 20032007 A NO20032007 A NO 20032007A NO 20032007 D0 NO20032007 D0 NO 20032007D0
Authority
NO
Norway
Prior art keywords
radiopharmaceuticals
alzheimer
diagnosis
disease
Prior art date
Application number
NO20032007A
Other languages
English (en)
Other versions
NO20032007L (no
Inventor
Christoph-Stephan Hilger
Bernd Johannsen
Joerg Steinbach
Peter Maeding
Meredith Halks-Miller
Richard Horuk
Harald Dinter
Raju Mohan
Joseph E Hesselgesser
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20032007D0 publication Critical patent/NO20032007D0/no
Publication of NO20032007L publication Critical patent/NO20032007L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20032007A 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom NO20032007L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24629900P 2000-11-06 2000-11-06
PCT/EP2001/012607 WO2002036581A1 (en) 2000-11-06 2001-11-01 Radiopharmaceuticals for diagnosing alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20032007D0 true NO20032007D0 (no) 2003-05-05
NO20032007L NO20032007L (no) 2003-07-02

Family

ID=22930075

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032007A NO20032007L (no) 2000-11-06 2003-05-05 Radiofarmasöytika for diagnostisering av Alzheimers sykdom

Country Status (29)

Country Link
US (2) US6676926B2 (no)
EP (1) EP1332138B1 (no)
JP (1) JP4234425B2 (no)
KR (1) KR20030045167A (no)
CN (1) CN1473158A (no)
AR (1) AR035366A1 (no)
AT (1) ATE314354T1 (no)
AU (2) AU1403402A (no)
BG (1) BG107762A (no)
BR (1) BR0115150A (no)
CA (1) CA2424598A1 (no)
DE (1) DE60116365T2 (no)
EA (1) EA006199B1 (no)
EE (1) EE200300216A (no)
HR (1) HRP20030459A2 (no)
HU (1) HUP0301710A3 (no)
IL (1) IL155191A0 (no)
JO (1) JO2207B1 (no)
MX (1) MXPA03003759A (no)
NO (1) NO20032007L (no)
NZ (1) NZ525303A (no)
PE (1) PE20020531A1 (no)
PL (1) PL361631A1 (no)
SK (1) SK287495B6 (no)
TW (1) TWI238820B (no)
UY (1) UY27003A1 (no)
WO (1) WO2002036581A1 (no)
YU (1) YU33203A (no)
ZA (1) ZA200304409B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
EA006243B1 (ru) 2001-10-22 2005-10-27 Пфайзер Продактс Инк. Производные пиперазина с антагонистической активностью к рецептору ccr1
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
PL1620373T3 (pl) * 2003-05-07 2008-09-30 Bayer Schering Pharma Ag Urządzenie i sposób fluorowania nukleofilowego
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
WO2005082425A1 (en) * 2004-02-24 2005-09-09 The General Hospital Corporation Catalytic radiofluorination
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR100778888B1 (ko) * 2005-11-29 2007-11-28 재단법인서울대학교산학협력재단 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물
KR101922515B1 (ko) 2006-09-08 2019-02-20 로드아일랜드하스피틀 알코올 유발성 간 질환의 치료, 예방 및 역행
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2094625A1 (en) * 2006-12-21 2009-09-02 Hammersmith Imanet, Ltd Radiolabelling methods
JP2011502966A (ja) * 2007-10-31 2011-01-27 アルセレス ファーマシューティカルズ, インコーポレイテッド ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法
AU2009225407B2 (en) 2008-03-21 2013-09-05 The General Hospital Corporation Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
EP2161256A1 (en) * 2008-09-08 2010-03-10 Atomic Energy Council - Institute of Nuclear Energy Research Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
WO2011041470A2 (en) * 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
TW201201846A (en) * 2010-02-08 2012-01-16 Bayer Schering Pharma Ag Iodo precursor for a PET imaging agent of amyloid plaques
WO2011110511A1 (en) * 2010-03-11 2011-09-15 Bayer Pharma Aktiengesellschaft Spect imaging agents of amyloid plaques
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
WO2015099094A1 (ja) 2013-12-27 2015-07-02 国立大学法人東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
WO2017040336A1 (en) * 2015-08-28 2017-03-09 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06510021A (ja) * 1991-03-13 1994-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミネソタ アルツハイマー病検出用の放射性薬剤
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
GB9413772D0 (en) 1994-07-08 1994-08-24 Wyeth John & Brother Ltd 5-HT1A ligands
US5919797A (en) * 1996-04-24 1999-07-06 Emory University Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト,インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AUPP818099A0 (en) 1999-01-14 1999-02-11 Fujisawa Pharmaceutical Co., Ltd. New n-containing heterocyclic compounds
KR20010108394A (ko) 1999-03-26 2001-12-07 다비드 에 질레스 신규 화합물
UY27003A1 (es) * 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer

Also Published As

Publication number Publication date
TWI238820B (en) 2005-09-01
DE60116365D1 (de) 2006-02-02
IL155191A0 (en) 2003-11-23
US6872381B1 (en) 2005-03-29
MXPA03003759A (es) 2003-07-28
NZ525303A (en) 2004-10-29
CN1473158A (zh) 2004-02-04
AU1403402A (en) 2002-05-15
SK5472003A3 (en) 2003-10-07
UY27003A1 (es) 2002-07-31
ZA200304409B (en) 2004-09-06
SK287495B6 (sk) 2010-12-07
DE60116365T2 (de) 2006-08-24
BR0115150A (pt) 2003-12-30
EP1332138B1 (en) 2005-12-28
JP2004513123A (ja) 2004-04-30
JO2207B1 (en) 2004-10-07
US6676926B2 (en) 2004-01-13
HRP20030459A2 (en) 2005-04-30
YU33203A (sh) 2006-05-25
AU2002214034B2 (en) 2006-01-05
PL361631A1 (en) 2004-10-04
EP1332138A1 (en) 2003-08-06
PE20020531A1 (es) 2002-06-15
ATE314354T1 (de) 2006-01-15
NO20032007L (no) 2003-07-02
KR20030045167A (ko) 2003-06-09
EA200300507A1 (ru) 2003-12-25
HUP0301710A2 (hu) 2003-11-28
JP4234425B2 (ja) 2009-03-04
US20020131932A1 (en) 2002-09-19
CA2424598A1 (en) 2002-05-10
EE200300216A (et) 2003-08-15
EA006199B1 (ru) 2005-10-27
HUP0301710A3 (en) 2007-03-28
AR035366A1 (es) 2004-05-12
WO2002036581A1 (en) 2002-05-10
BG107762A (en) 2004-03-31

Similar Documents

Publication Publication Date Title
NO20032007D0 (no) Radiofarmasöytiske midler for diagnose av Alzheimer's sykdom
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
PT2264018E (pt) Derivados de tioflavina para uso no diagnóstico da doença de alzheimer
NO20002380D0 (no) Forbindelser for før-døden diagnose av Alzheimers sykdom og in vivo billeddannelse, samt forhindring av amyloid deponering
NO20030059L (no) Tidlig diagnose av konformasjonssykdommer
AU2610901A (en) Predictive diagnostic for alzheimer's disease
AU3891499A (en) Diagnostic tests for alzheimer's disease
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
NO20002686L (no) Forbedring av Peyronies sykdom
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
ZA200603178B (en) Quick test for the diagnosis of Alzheimer's disease
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
ITMI20010985A0 (it) Farmaci per il morbo di alzheimer
NO20010953D0 (no) En fremgangsmÕte for behandling av stafylokokkal sykdom
HUP0003684A3 (en) Diagnostic test for alzheimer's disease
DE69825888D1 (de) Diagnostisches verfahren der alzheimer-erkrankung
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
ITMI20021578A1 (it) Procedimento per l'esecuzione di una diagnosi in autoveicoli
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
GB0012123D0 (en) Alzheimer's disease assay
AU2002364885A8 (en) Alzheimer's disease model
FR2766927B1 (fr) Methodes et kits pour le diagnostic de la maladie d'alzheimer
GB0127473D0 (en) Compounds for imaging alzheimer's disease
SE9901466D0 (sv) Nucleic acids for diagnosing and modeling alzheimer's disease